Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Nature Medicine|October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
Nature Medicine|January 26, 2023
Persistent mutation burden drives sustained anti-tumor immune responsesNoushin Niknafs, Archana Balan, Christopher Cherry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2026
plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid TumorsJenna V Canzoniero, Daniel Rabizadeh, Ilias Ziakas, et al.
Cancer Research|September 8, 2022
Genomic Landscapes and Hallmarks of Mutant RAS in Human CancersRobert B Scharpf, Archana Balan, Biagio Ricciuti, et al.
Cell Reports. Medicine|December 9, 2020
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in MelanomaValsamo Anagnostou, Daniel C Bruhm, Noushin Niknafs, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapyMichael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, et al.
Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung CancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Pageof 2